ReviewReviews in endocrine & metabolic disorders2017
Cyto-histology in NET: what is necessary today and what is the future?
Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Mixed Neuroendocrine Carcinoma and Adenocarcinoma in a Patient With Ileal Pouch-Anal Anastomosis.ACG case reports journal · 2026Article
- SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix.Virchows Archiv : an international journal of pathology · 2022Article
- Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.Endocrine pathology · 2022Review
- Neuroendocrine tumor (NET) of the vagina in the light of WHO 2020 2-tiered grading system: clinicopathological report of the first described case.Virchows Archiv : an international journal of pathology · 2022Article
- Review
- Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?Journal of translational medicine · 2021Article
- Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.Frontiers in endocrinology · 2021Observational
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.Nutrients · 2018Article
- Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2018Review
- Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.Reviews in endocrine & metabolic disorders · 2018Review
- Significance of cytodiagnosis in primary carcinoid tumor of the middle ear: A case report.Oncology letters · 2018Article
- Grading of Neuroendocrine Carcinomas: Correlation ofDisease markers · 2018Article
- Management of neuroendocrine tumors of unknown primary.Reviews in endocrine & metabolic disorders · 2017Review
- Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.Reviews in endocrine & metabolic disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The carcinoid as originally described is part of the relatively large family of neuroendocrine neoplasia found in almost every organ. Historical reasons back their current definitions. Neuroendocrine cancer is most frequently observed in the lung and the digestive tract. In the lung is defined as carcinoid (typical and atypical) for well differentiated, low to intermediate grade, and small cell and large cell neuroendocrine carcinoma for poorly differentiated, high grade. In the digestive system are respectively defined as neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) of small and large cell types. Grading and staging are developed for their clinical classification by the World Health Organization (WHO) and the American Joint Committee on Cancer (AJCC). In both anatomical sites the morphological features are overlapping, with bland histology for carcinoid and NET, and aggressive features with extensive necrosis, severe atypia and abundant, atypical mitoses for high grade cancer types. Such features are also essential diagnostic clues in cytological preparations. The confirmation of the neuroendocrine signature by immunohistochemistry is mandatory for the diagnosis; a minimum panel comprising chromogranin A and synaptophysin is recommended in the digestive system. In addition, the application of grading requires the mitotic count and or spotty necrosis assessment for lung, or the mitotic count and the Ki67 assessment in the digestive system.
Indexed as
Identifiers
28871510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.